$ALX

Alexander’s Completes Sale of Rego Park I

Alexander’s, Inc. (NYSE: ALX) said it completed the sale of its Rego Park I property in Queens, New York, to Northwell Health. The gross price was $235.5 million and net proceeds were $203 million; it received $224 million at closing after paying $21 million of costs. The company expects a ~$148 million financial statement gain in Q2 and ~$145 million tax gain, with $48 million in 2025 and ~$97 million in 2026.

Original reporting
Published May 28, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 28, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alexander’s Completes Sale of Rego Park I — source image
Decision brief

The 30-second read

$ALXBullishMed
01

Why it matters

Completion confirms deal economics and provides explicit accounting/tax gain timing, which should feed directly into Q2 financial modeling and guidance expectations.

02

Market read

A completed, large NYC property sale with specified Q2 gain recognition is a concrete catalyst for ALX’s near-term earnings narrative.

03

What to watch

Traders may discount the impact if ALX’s core FFO/recurring earnings are unchanged and if proceeds are not clearly tied to accretive reinvestment or debt reduction.

Relevance 9/10Novelty 8/10Timing: After-hours/overnight—gain recognition scheduled for Q2

Background

Alexander’s is a NYC-focused REIT; it previously announced the sale of its Rego Park I property in Queens to Northwell Health.

Company-level read

Ticker impact

$ALXBullishMedium confidence
Context

Alexander’s completed the sale of Rego Park I to Northwell Health, locking in $235.5M gross price and ~$148M gain to Q2 results.

Expected impact

Near-term support for ALX as investors model the Q2 gain; limited upside beyond expectations if already priced in.

Evidence & confidence

The article provides concrete deal economics (gross/net proceeds) and explicit timing for gain recognition (Q2), which can directly affect reported earnings and REIT performance metrics.

Market effects

Reinforces that NYC REIT asset sales can crystallize large gains, potentially supporting sector sentiment around monetization of stabilized assets.

Highlights continued demand for NYC healthcare-linked real estate (buyer: Northwell Health) in Queens.

Low—primarily company-specific asset monetization with limited cross-border read-across.

Counterpoint

If the gain is largely non-cash or tax-driven, equity reaction may be muted versus what headline gain suggests.

Key entities

  • Alexander’s, Inc.

    NYC REIT completing the Rego Park I property sale.

  • Northwell Health, Inc.

    Healthcare system purchasing Rego Park I property.

Related articles

$ALXMedAI 8/10

A $148M Sale Masks What Alexander’s (ALX) Really Earned

Alexander’s Inc. (ALX) reported Q2 net income of $155.4M, up 25x YoY, driven by a $148M gain from selling one property. FFO rose to $15.5M, and revenue increased to $54.7M. However, H1 2026 FFO declined to $28.9M, while revenue edged up to $108.1M. Hedge fund interest grew, but short interest remains high at 13.73%.

$ALXMed

Cebu shipping firm files for IPO

Aznar Shipping Corp. filed for an IPO of up to 1 billion primary shares at P0.67 each, potentially raising P670 million. The company may also offer 100 million secondary shares, adding P67 million if fully exercised. Proceeds will fund fleet expansion and other capital expenditures. The IPO is scheduled for December 2026 on the Philippine Stock Exchange under the ticker ALX.

$ALXMed

Are Atlas Arteria Shares Overvalued? The Street View

Atlas Arteria (ASX: ALX) shares are up 4.72% YTD and trade around A$5.10, with a ~7% dividend yield. RBC Capital Markets downgraded the stock to Underperform and set a A$4.75 price target, citing liquidity concerns as IFM Investors’ hostile bid nears 40–45% and risks to distribution sustainability. IFM’s offer is A$4.75, rising to A$5.10 at 45% ownership.